Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

NCT06041490 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Liver Transplant; Complications
Hepatocarcinoma
Recurrent Osteosarcoma
High-Risk Cancer

Interventions

DRUG: multi-kinase inhibitors in combination with bevacizumab

Sponsor

Peking Union Medical College Hospital